Compare Biogen Inc (BIIB) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Expensify Inc — how do they compare? Biogen Inc trades at $197.97 (market cap $28.34B), while Expensify Inc trades at $1.79 (market cap $175.04M). The key difference: Biogen Inc is far larger — about 161.9× Expensify Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Expensify Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | EXFY | |
|---|---|---|
Market Cap | $28.34B | $175.04M |
Sector | Health | Technology |
52-Week High | $216.63 | $2.33 |
52-Week Low | $122.68 | $0.75 |
Enterprise Value | $30.62B | $114.07M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Expensify (EXFY) trades at $1.79, down 5.29% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.04, beating expectations, but maintains negative net income margins. Recent news highlights product launches including AI-powered expense automation and a $25 million stock buyback program. Revenue remains stable around $140 million annually with improving cash flow from operations.
Outlook remains mixed with analyst consensus evenly split between Buy and Hold. Key opportunities include product innovation and cost management, while risks involve persistent profitability challenges and competitive pressure in expense management software. The stock's valuation shows high P/E ratio despite negative earnings, requiring careful fundamental assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
